1 week Ago By Defense World Staff
Legal & General Group Plc lifted its position in Liquidia Co. ( NASDAQ:LQDA – Free Report ) by 6.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The fund owned 83,286 shares of the company’s stock after acquiring an additional 5,048 shares during the quarter. Legal & General Group Plc owned 0.10% of Liquidia worth $979,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in LQDA. Barclays PLC lifted its position in shares of Liquidia by 265.0% during the third quarter.
Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after purchasing an additional 72,591 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Liquidia by 855.
3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after buying an additional 210,753 shares in the last quarter.
Charles Schwab Investment Management Inc. boosted its position in Liquidia by 9.8% in the 4th quarter.
Charles Schwab Investment Management Inc. now owns 428,570 shares of the company’s stock valued at $5,040,000 after buying an additional 38,313 shares during the period. Bank of New York Mellon Corp grew its stake in Liquidia by 3.
3% in the 4th quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company’s stock worth $2,218,000 after acquiring an additional 6,034 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Liquidia during the fourth quarter worth approximately $169,000.
64.54% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades Several research analysts recently issued reports on the company.
Scotiabank reissued an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th.
Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock.
According to data from MarketBeat.com, Liquidia currently has an average rating of “Buy” and a consensus price target of $26.63.
Liquidia Stock Up 0.6 % NASDAQ:LQDA opened at $14.12 on Monday.
The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -8.66 and a beta of 0.
23. Liquidia Co. has a 52 week low of $8.
26 and a 52 week high of $16.81. The firm has a 50 day moving average of $14.
40 and a 200 day moving average of $12.92. Liquidia ( NASDAQ:LQDA – Get Free Report ) last posted its quarterly earnings data on Wednesday, March 19th.
The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.
08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.
38%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.
60 million. As a group, analysts expect that Liquidia Co. will post -1.
51 EPS for the current year. Insider Activity In other news, CFO Michael Kaseta sold 8,283 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.
57, for a total value of $112,400.31. Following the completion of the transaction, the chief financial officer now directly owns 396,315 shares in the company, valued at $5,377,994.
55. This trade represents a 2.05 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Also, insider Jason Adair sold 1,856 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.
57, for a total value of $25,185.92. Following the completion of the sale, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.
28. This represents a 1.00 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold a total of 32,683 shares of company stock worth $443,753 over the last 90 days. 30.
10% of the stock is currently owned by corporate insiders. About Liquidia ( Free Report ) Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Recommended Stories Five stocks we like better than Liquidia How to Read Stock Charts for Beginners Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery Stock Market Sectors: What Are They and How Many Are There? O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors Top Biotech Stocks: Exploring Innovation Opportunities Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2 Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter ..
